Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM0306S
- Development stage
- Phase 3
- Lead developer
- ImmuneOnco
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
IMM0306S is an investigational subcutaneous formulation of amulirafusp alfa (IMM0306), a first-in-class bispecific CD20×CD47 antibody fusion protein developed by ImmuneOnco Biopharmaceuticals. Built on the proprietary 'mAb-Trap' platform, the molecule consists of a CD20-targeting monoclonal antibody fused to the CD47-binding domain of SIRPα. This dual-targeting mechanism simultaneously binds CD20 on B cells and CD47, blocking the CD47-SIRPα 'don't eat me' inhibitory signal while promoting B-cell depletion via Fcγ receptor-mediated phagocytosis and NK cell activation. Unlike some other CD47-targeting therapies, amulirafusp alfa is designed to avoid binding to human red blood cells, reducing the risk of treatment-induced anemia. IMM0306S is being developed for B-cell-mediated autoimmune diseases, with clinical evaluation currently underway in a Phase Ib trial for systemic lupus erythematosus (SLE).
- Other names
- subcutaneous IMM0306subcutaneous amulirafusp alfa
02
Targets
CD20 (B-lymphocyte antigen CD20)CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on IMM0306S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM0306S.